Denali Therapeutics’ (DNLI) “Overweight” Rating Reaffirmed at JPMorgan Chase & Co.

Denali Therapeutics (NASDAQ:DNLI)‘s stock had its “overweight” rating restated by stock analysts at JPMorgan Chase & Co. in a note issued to investors on Monday,Benzinga reports. They presently have a $29.00 price target on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 12.93% from the company’s previous close.

DNLI has been the topic of several other research reports. Sanford C. Bernstein reissued a “hold” rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. Stifel Nicolaus set a $41.00 price objective on shares of Denali Therapeutics in a research note on Monday, June 22nd. HC Wainwright boosted their price objective on shares of Denali Therapeutics from $32.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Robert W. Baird increased their target price on shares of Denali Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Finally, The Goldman Sachs Group lifted their price target on shares of Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Denali Therapeutics Price Performance

Shares of NASDAQ:DNLI opened at $25.68 on Monday. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 12 month low of $12.58 and a 12 month high of $27.30. The company has a 50-day moving average price of $21.79 and a 200 day moving average price of $20.38. The company has a market cap of $4.08 billion, a price-to-earnings ratio of -8.92 and a beta of 0.96.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same period in the previous year, the business posted ($0.78) earnings per share. As a group, equities research analysts predict that Denali Therapeutics will post -2.77 earnings per share for the current year.

Institutional Trading of Denali Therapeutics

A number of large investors have recently made changes to their positions in DNLI. E. Ohman J or Asset Management AB bought a new position in shares of Denali Therapeutics in the second quarter worth about $4,115,000. Handelsbanken Fonder AB lifted its holdings in Denali Therapeutics by 36.1% during the 2nd quarter. Handelsbanken Fonder AB now owns 59,600 shares of the company’s stock valued at $1,533,000 after buying an additional 15,800 shares in the last quarter. Defilade Capital Management L.P. boosted its position in Denali Therapeutics by 107.1% in the 1st quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company’s stock valued at $26,111,000 after buying an additional 703,256 shares during the period. Seven Fleet Capital Management LP bought a new position in Denali Therapeutics in the 1st quarter worth about $677,000. Finally, Groupama Asset Managment increased its position in shares of Denali Therapeutics by 36.6% during the first quarter. Groupama Asset Managment now owns 207,130 shares of the company’s stock worth $3,977,000 after acquiring an additional 55,539 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.